CY1123160T1 - Αποκαρβοξυλαση γλουταμικου οξεος (gad) για χρηση στην αγωγη αυτοανοσης παθησης - Google Patents

Αποκαρβοξυλαση γλουταμικου οξεος (gad) για χρηση στην αγωγη αυτοανοσης παθησης

Info

Publication number
CY1123160T1
CY1123160T1 CY20201100694T CY201100694T CY1123160T1 CY 1123160 T1 CY1123160 T1 CY 1123160T1 CY 20201100694 T CY20201100694 T CY 20201100694T CY 201100694 T CY201100694 T CY 201100694T CY 1123160 T1 CY1123160 T1 CY 1123160T1
Authority
CY
Cyprus
Prior art keywords
composition
beta cell
antigen
vitamin
cell autoantigen
Prior art date
Application number
CY20201100694T
Other languages
Greek (el)
English (en)
Inventor
Anders Essen-Möller
Johnny Ludvigsson
Original Assignee
Diamyd Medical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diamyd Medical Ab filed Critical Diamyd Medical Ab
Publication of CY1123160T1 publication Critical patent/CY1123160T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01005—Acetolactate decarboxylase (4.1.1.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CY20201100694T 2014-06-04 2020-07-28 Αποκαρβοξυλαση γλουταμικου οξεος (gad) για χρηση στην αγωγη αυτοανοσης παθησης CY1123160T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1450678 2014-06-04
SE1451315 2014-11-04
PCT/SE2015/050651 WO2015187087A2 (en) 2014-06-04 2015-06-04 Novel combinations for antigen based therapy

Publications (1)

Publication Number Publication Date
CY1123160T1 true CY1123160T1 (el) 2021-10-29

Family

ID=54767532

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100694T CY1123160T1 (el) 2014-06-04 2020-07-28 Αποκαρβοξυλαση γλουταμικου οξεος (gad) για χρηση στην αγωγη αυτοανοσης παθησης

Country Status (20)

Country Link
US (3) US20170196949A1 (enExample)
EP (2) EP3760224A3 (enExample)
JP (2) JP6686007B2 (enExample)
CN (2) CN106535926B (enExample)
AU (3) AU2015268960B2 (enExample)
CA (2) CA3210184A1 (enExample)
CY (1) CY1123160T1 (enExample)
DK (1) DK3151853T3 (enExample)
ES (1) ES2807787T3 (enExample)
HU (1) HUE051151T2 (enExample)
IL (3) IL300130B2 (enExample)
LT (1) LT3151853T (enExample)
PL (1) PL3151853T3 (enExample)
PT (1) PT3151853T (enExample)
RS (1) RS60581B1 (enExample)
RU (1) RU2702632C2 (enExample)
SI (1) SI3151853T1 (enExample)
SM (1) SMT202000384T1 (enExample)
WO (1) WO2015187087A2 (enExample)
ZA (1) ZA202204777B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6827113B2 (ja) 2017-01-21 2021-02-10 広州白雲山漢方現代薬業有限公司Ｇｕａｎｇｚｈｏｕ Ｈａｎｆａｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ． シェーグレン症候群の治療におけるペオニフロリン−６’−ｏ−ベンゼンスルホン酸の使用
JP7413254B2 (ja) 2017-09-08 2024-01-15 ダイアミド・メディカル・アクチボラゲット 改善された免疫療法
SI3678692T1 (sl) * 2017-09-08 2022-04-29 Diamyd Medical Ab Stratifikacija genotipa pri zdravljenju in preprečevanju sladkorne bolezni
EP3749354A4 (en) * 2018-02-05 2021-11-03 Diamyd Medical AB NEW COMPOSITION AND ITS USE
CA3092939C (en) * 2018-03-07 2024-10-08 Atnx Spv, Llc USE OF THE COMBINATION OF KX01 AND VITAMIN D TO TREAT HYPERPROLIFERATIVE SKIN DISORDERS
US10500217B2 (en) * 2018-04-30 2019-12-10 Leslie Ray Matthews, M.D., Llc Vitamin D3, heat shock proteins, and glutathione for the treatment of chronic inflammation and chronic diseases
WO2020210798A1 (en) * 2019-04-12 2020-10-15 Loma Linda University Methods for treatment of niemann-pick disease type c
US20230414878A1 (en) * 2020-11-16 2023-12-28 W. L. Gore & Associates, Inc. Formulations, methods, and pre-filled injection devices without fatty acid particles
WO2022155188A1 (en) * 2021-01-13 2022-07-21 University Of Maryland, College Park Methods and platforms for promoting antigen-specific tolerance in the treatment of type 1 diabetes and graft rejection and compositions relating thereto
US20240277768A1 (en) * 2021-06-17 2024-08-22 Tihamer Orban Individualized Cell Therapy Using Patient-Derived Antigen-Specific Regulatory T Cells
WO2023066881A1 (en) * 2021-10-18 2023-04-27 Astrazeneca Ab Inhibition of map3k15 for treating and preventing diabetes

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
AU7369096A (en) * 1995-09-21 1997-04-09 University Of Utah Research Foundation Targeting of conjugates of poly(ethylene glycol) and antibodies against glutamic acid decarboxylase to islet cells
SE9503379D0 (sv) * 1995-09-29 1995-09-29 Synectics Medical Ab A modified GAD, a method for producing a modified GAD, a method for supplying a modified GAD, a peptide and the use of an ordinary and/or a modified GAD
US6884785B2 (en) * 1999-06-17 2005-04-26 The Scripps Research Institute Compositions and methods for the treatment or prevention of autoimmune diabetes
EP1446129A4 (en) * 2001-11-21 2006-05-10 Univ Leland Stanford Junior POLYNUCLEOTIDE THERAPY
US20050152914A1 (en) * 2003-06-13 2005-07-14 Diamyd, Inc. Formulation of antigen
AU2005213449A1 (en) * 2004-02-04 2005-08-25 The La Jolla Institute For Allergy And Immunology Anti-CD3 and antigen-specific immunotherapy to treat autoimmunity
WO2005102374A2 (en) * 2004-03-03 2005-11-03 Diamyd Medical Ab Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
CN101365494A (zh) * 2005-10-05 2009-02-11 贝希尔治疗学股份有限公司 治疗自身免疫性疾病的组合物和方法
US9023984B2 (en) * 2006-12-29 2015-05-05 The Regents Of The University Of Colorado, A Body Corporate Diagnostic and therapeutic target for autoimmune diseases and uses thereof
EP3269384A1 (en) * 2007-03-07 2018-01-17 Uti Limited Partnership Compositions and methods for the prevention and treatment of autoimmune conditions
RU2009143345A (ru) * 2007-04-24 2011-05-27 Диамид Терапьютикс Аб (Se) Лекарственные средства и способы для лечения аутоиммунного заболевания и рака
EP2620157A3 (en) * 2007-10-12 2013-10-16 Massachusetts Institute of Technology Vaccine nanotechnology
CN103768580A (zh) * 2007-12-19 2014-05-07 托勒兰泽亚股份公司 治疗自身免疫和过敏性疾病的组合物及方法
EP2621282B1 (en) * 2010-09-28 2020-04-15 The Regents of The University of California Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
WO2012062697A1 (en) * 2010-11-08 2012-05-18 Novartis Ag Combination therapy for type 1 diabetes
DE102011018499A1 (de) * 2011-04-23 2012-10-25 Emc Microcollections Gmbh Topische Nanopartikel-Vakzine zur Immunstimulation der dendritischen Zellen in der Haut
US8735359B2 (en) * 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes

Also Published As

Publication number Publication date
RU2702632C2 (ru) 2019-10-09
IL249250B (en) 2020-03-31
IL300130A (en) 2023-03-01
WO2015187087A3 (en) 2016-01-28
PT3151853T (pt) 2020-07-27
AU2022202003B2 (en) 2024-12-12
EP3151853B1 (en) 2020-05-06
RU2016150656A3 (enExample) 2019-01-25
IL300130B1 (en) 2024-01-01
RU2016150656A (ru) 2018-07-10
RS60581B1 (sr) 2020-08-31
SMT202000384T1 (it) 2020-09-10
EP3760224A3 (en) 2021-03-31
AU2015268960B2 (en) 2020-04-09
CA2950893A1 (en) 2015-12-10
JP6686007B2 (ja) 2020-04-22
HUE051151T2 (hu) 2021-03-01
JP2020125300A (ja) 2020-08-20
JP2017516870A (ja) 2017-06-22
ES2807787T3 (es) 2021-02-24
WO2015187087A2 (en) 2015-12-10
EP3151853A4 (en) 2018-04-25
CN106535926B (zh) 2022-02-01
PL3151853T3 (pl) 2020-11-02
LT3151853T (lt) 2020-08-10
ZA202204777B (en) 2024-09-25
AU2020203169A1 (en) 2020-06-04
US20170196949A1 (en) 2017-07-13
CA3210184A1 (en) 2015-12-10
CN114504639A (zh) 2022-05-17
IL273265B2 (en) 2023-06-01
IL300130B2 (en) 2024-05-01
US20240299514A1 (en) 2024-09-12
EP3760224A2 (en) 2021-01-06
IL249250A0 (en) 2017-02-28
AU2020203169B2 (en) 2021-12-23
SI3151853T1 (sl) 2020-10-30
CA2950893C (en) 2023-10-10
AU2022202003A1 (en) 2022-04-14
CN106535926A (zh) 2017-03-22
US20220000995A1 (en) 2022-01-06
DK3151853T3 (da) 2020-07-27
AU2015268960A1 (en) 2016-12-15
RU2019129803A (ru) 2020-12-14
EP3151853A2 (en) 2017-04-12
IL273265A (en) 2020-04-30

Similar Documents

Publication Publication Date Title
CY1123160T1 (el) Αποκαρβοξυλαση γλουταμικου οξεος (gad) για χρηση στην αγωγη αυτοανοσης παθησης
Wik et al. T cell metabolism in infection
Hossain et al. Reinvigorating exhausted CD8+ cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy
Roy et al. Methionine metabolism shapes T helper cell responses through regulation of epigenetic reprogramming
Hill et al. Glycogen synthase kinase‐3 controls IL‐10 expression in CD4+ effector T‐cell subsets through epigenetic modification of the IL‐10 promoter
Ma et al. Serine is an essential metabolite for effector T cell expansion
Silva-Cayetano et al. Spatial dysregulation of T follicular helper cells impairs vaccine responses in aging
Fernando et al. The pro-inflammatory cytokine, interleukin-6, enhances the polarization of alternatively activated macrophages
Weiskirchen et al. Cellular and molecular functions of hepatic stellate cells in inflammatory responses and liver immunology
Zanetti A second chance for telomerase reverse transcriptase in anticancer immunotherapy
Leavenworth et al. A p85α-osteopontin axis couples the receptor ICOS to sustained Bcl-6 expression by follicular helper and regulatory T cells
CY1120622T1 (el) Μεθοδοι και συνθεσεις για επαγωγη μιας ανοσιακης αποκρισης ως προς egfrviii
Nair et al. DNA demethylation of the Foxp3 enhancer is maintained through modulation of ten-eleven-translocation and DNA methyltransferases
Ohradanova-Repic et al. Extracellular purine metabolism is the switchboard of immunosuppressive macrophages and a novel target to treat diseases with macrophage imbalances
Gao et al. Synergy between IL-6 and TGF-β signaling promotes FOXP3 degradation
Jost et al. Changes in cytokine levels and NK cell activation associated with influenza
CY1121258T1 (el) Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων των ογκων των νευρωνων και του εγκεφαλου
BR112017018770A2 (pt) redução da tolerância imunológica induzida por pd-l1
BR112021026382A2 (pt) Uso de células t de receptor de antígenos quimérico e inibidores de células nk para tratamento de câncer
BR112015029953A2 (pt) anticorpos anti-tweakr e seus usos
WO2015143343A2 (en) Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
WO2015112749A3 (en) Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
MX2019000022A (es) Células veto generadas a partir de linfocitos t de memoria.
EP3024482A2 (en) Methods for diagnosing and treating immune disease
Rashu et al. Targeting the MR1-MAIT cell axis improves vaccine efficacy and affords protection against viral pathogens